Holen Sie sich die Stockscreener-App
6.03
2.11%
-0.13
Handel nachbörslich:
6.09
0.06
+1.00%
Schlusskurs vom Vortag:
$6.16
Offen:
$6.4577
24-Stunden-Volumen:
45,153
Relative Volume:
1.20
Marktkapitalisierung:
$179.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-1.77M
KGV:
-40.55
EPS:
-0.1487
Netto-Cashflow:
$-1.46M
1W Leistung:
+9.04%
1M Leistung:
+48.89%
6M Leistung:
+103.72%
1J Leistung:
+0.00%
1-Tages-Spanne:
$6.0098
$6.5798
1-Wochen-Bereich:
$5.375
$6.60
52-Wochen-Spanne:
$2.5701
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
Firmenname
Turn Therapeutics Inc
Sektor
Branche
Telefon
(818) 564-4011
Adresse
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
6.03 | 191.24M | 0 | -1.77M | -1.46M | -0.1487 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-29 | Eingeleitet | D. Boral Capital | Buy |
Turn Therapeutics Inc Aktie (TTRX) Neueste Nachrichten
Number of shareholders of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Turn Therapeutics Inc. (TTRX) Q1 2026 Earnings: Slight EPS Miss Amid Pre-Revenue Stage; Shares Rise - newsline.com
TTRX Q1 2026 Earnings: Narrow EPS Miss Highlights Ongoing Development PhaseRevenue Miss Report - newsline.com
TTRX Q1 2026 Earnings: Slight EPS Miss as Company Reports Loss Per Share of -$0.026Quarterly Profit Report - newsline.com
2 Large-Cap Stocks Worth Your Attention and 1 We Turn Down - Yahoo Finance
TTRX Q1 2026 Earnings: EPS Misses Estimates, Shares Fall 4.6%Profit Margin Analysis - newsline.com
2 Software Stocks to Keep an Eye On and 1 We Turn Down - Yahoo Finance
2 Financials Stocks to Target This Week and 1 We Turn Down - Yahoo Finance
TTRX: GX-03 shows rapid, biologic-level efficacy and safety in eczema, with broad expansion plans - TradingView
Turn Therapeutics Highlights GX-03 Phase 2 Atopic Dermatitis Data - TipRanks
Turn Therapeutics posts positive GX-03 Phase 2 interim results, updates investor presentation - TradingView
Turn Therapeutics (NASDAQ: TTRX) details GX-03 interim data, onychomycosis plans and runway - Stock Titan
Turn Therapeutics reports interim phase 2 data for eczema drug By Investing.com - Investing.com Australia
Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch - RTTNews
Turn Therapeutics Shares Higher on Favorable Interim Eczema Drug Results - Moomoo
Phase II bid Turns out safe, EASI, effective; AD topical island? - BioWorld News
Turn Therapeutics reports interim phase 2 data for eczema drug - Investing.com UK
Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data - TipRanks
Turn Therapeutics’ GX-03 Shows Rapid and Significant Efficacy in Phase 2 Atopic Dermatitis Trial with Strong Safety Profile 123 - Minichart
Turn Therapeutics interim Phase 2 analysis shows rapid, deep EASI responses and favorable safety for GX-03 - TradingView
Turn Therapeutics reports interim analysis findings and adaptive optimization strategy from phase 2 GX-03 trial in moderate-to-severe atopic dermatitis - marketscreener.com
Turn Therapeutics Reports Interim Analysis Findings And Adaptive Optimization Strategy From Phase 2 GX-03 Trial In Moderate-To-Severe Atopic Dermatitis - TradingView
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - The Joplin Globe
Turn Therapeutics publishes GX-03 dermatitis study results - Investing.com UK
Turn Therapeutics highlights GX-03 preclinical data in dermatitis - TipRanks
Turn Therapeutics publishes GX-03 dermatitis study results By Investing.com - Investing.com Australia
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model - Business Wire
Turn Therapeutics Inc. (TTRX) Q1 2026 Earnings: Narrow EPS Miss Overshadowed by Operational ProgressReturn On Assets - thelegaladvocate.com
TTRX Q1 2026 Earnings: Narrow Loss Slightly Misses Estimates as Pre-Revenue Biotech Advances Pipeline - Newser
Turn Therapeutics (TTRX) Q1 2026 Earnings: Narrow EPS Miss Amid Modest Stock GainsProfit Guidance Range - Newser
Turn Therapeutics (TTRX) Stock Trend: +2.10% Higher, $5.11 the Next Hurdle 2026-05-21Pro Trader Picks - Newser
Turn Therapeutics to Present GX-03 Atopic Dermatitis Therapy Updates at Jefferies Global Healthcare Conference 2026 12 - Minichart
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 - PharmiWeb.com
Turn Therapeutics CEO to Present at Jefferies Conference - TipRanks
Turn Therapeutics to Present at Jefferies Global Healthcare Conference June 4 - TradingView
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen Hahn to Lead Clinical and Regulatory Strategy for GX-03 Atopic Dermatitis Therapy 1 - Minichart
Turn Therapeutics Appoints Former FDA Chief to Lead GX-03 - TipRanks
Turn Therapeutics Recruits Former FDA Commissioner Stephen Hahn to Guide Eczema Drug Development - citybiz
Turn Therapeutics appoints former FDA chief Stephen Hahn - Investing.com
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead - Weekly Voice
Turn Therapeutics appoints former FDA chief Stephen Hahn By Investing.com - Investing.com Canada
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Turn Therapeutics (TTRX) Stock: Up +1.25%, Key Resistance at $4.26 2026-05-14Mid Cap Momentum - newser.com
Turn Therapeutics (Direct Listing) (TTRX) Earnings Calendar_Earnings Analysis_Financial Report and Earnings Call - Tiger Brokers
Turn Therapeutics Reports First Quarter 2026 Financial Results - TradingView
Turn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - standard-journal.com
The key trends fueling Turn Therapeutics (TTRX) growth potential (-2.37%) 2026-05-11Elite Trading Signals - newser.com
Finanzdaten der Turn Therapeutics Inc-Aktie (TTRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Turn Therapeutics Inc-Aktie (TTRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GOLDEN ARTHUR F | Director |
Nov 24 '25 |
Buy |
3.44 |
9,868 |
33,946 |
60,602 |
| GOLDEN ARTHUR F | Director |
Nov 21 '25 |
Buy |
2.87 |
20,532 |
58,927 |
50,734 |
| Chaudhary Zuraiz | See Remarks |
Nov 20 '25 |
Buy |
2.61 |
1,450 |
3,784 |
9,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 21 '25 |
Buy |
3.29 |
1,000 |
3,290 |
10,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 17 '25 |
Buy |
3.62 |
2,500 |
9,050 |
7,550 |
| Chesed Abraham | Board Observer |
Oct 23 '25 |
Buy |
4.60 |
14,286 |
65,716 |
1,447,268 |
| Chaudhary Zuraiz | See Remarks |
Oct 23 '25 |
Buy |
4.95 |
5,050 |
24,998 |
5,050 |
| GOLDEN ARTHUR F | Director |
Oct 23 '25 |
Buy |
4.95 |
20,202 |
100,000 |
30,202 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):